Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1995 Dec;32(12):934–937. doi: 10.1136/jmg.32.12.934

Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.

C Eng 1, P A Crossey 1, L M Mulligan 1, C S Healey 1, C Houghton 1, A Prowse 1, S L Chew 1, P L Dahia 1, J L O'Riordan 1, S P Toledo 1, et al.
PMCID: PMC1051771  PMID: 8825918

Abstract

Phaeochromocytomas may occur sporadically, or as part of the inherited cancer syndromes multiple endocrine neoplasia (MEN) type 2, von Hippel-Lindau disease (VHL), and, rarely, in type 1 neurofibromatosis. In MEN 2, germline missense mutations have been found in one of eight codons within exons 10, 11, 13, 14, and 16 of the RET proto-oncogene. In VHL, germline mutations within one of the three exons are responsible for the majority of cases. To determine if somatic mutations similar to those seen in the germline in MEN 2 or VHL disease play a role in the pathogenesis of sporadic or familial phaeochromocytomas, we analysed 48 sporadic tumours and tumours from 17 MEN 2 and five VHL patients for mutations in RET exons 9, 10, 11, 13, 14, 15, and 16, and the entire coding sequence of VHL. Five of 48 sporadic phaeochromocytomas had RET mutations within exons 10, 11, and 16. Of these, one was proven to be germline and two were proven to be somatic mutations. Four of 48 had VHL mutations; these included both the bilateral cases in the series (one was proven to be a germline mutation) and two others, of which one was proven somatic.

Full text

PDF
934

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atuk N. O., McDonald T., Wood T., Carpenter J. T., Walzak M. P., Donaldson M., Gillenwater J. Y. Familial pheochromocytoma, hypercalcemia, and von Hippel-Lindau disease. A ten year study of a large family. Medicine (Baltimore) 1979 May;58(3):209–218. doi: 10.1097/00005792-197905000-00001. [DOI] [PubMed] [Google Scholar]
  2. Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., Chabrier G., Houdent C., Murat A., Schlumberger M. RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995 Jun 15;10(12):2415–2419. [PubMed] [Google Scholar]
  3. Carlson K. M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C. E., Wells S. A., Jr, Goodfellow P. J., Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579–1583. doi: 10.1073/pnas.91.4.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen F., Kishida T., Yao M., Hustad T., Glavac D., Dean M., Gnarra J. R., Orcutt M. L., Duh F. M., Glenn G. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat. 1995;5(1):66–75. doi: 10.1002/humu.1380050109. [DOI] [PubMed] [Google Scholar]
  5. Crossey P. A., Foster K., Richards F. M., Phipps M. E., Latif F., Tory K., Jones M. H., Bentley E., Kumar R., Lerman M. I. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet. 1994 Jan;93(1):53–58. doi: 10.1007/BF00218913. [DOI] [PubMed] [Google Scholar]
  6. Crossey P. A., Richards F. M., Foster K., Green J. S., Prowse A., Latif F., Lerman M. I., Zbar B., Affara N. A., Ferguson-Smith M. A. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994 Aug;3(8):1303–1308. doi: 10.1093/hmg/3.8.1303. [DOI] [PubMed] [Google Scholar]
  7. Donis-Keller H., Dou S., Chi D., Carlson K. M., Toshima K., Lairmore T. C., Howe J. R., Moley J. F., Goodfellow P., Wells S. A., Jr Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 1993 Jul;2(7):851–856. doi: 10.1093/hmg/2.7.851. [DOI] [PubMed] [Google Scholar]
  8. Eng C., Mulligan L. M., Smith D. P., Healey C. S., Frilling A., Raue F., Neumann H. P., Pfragner R., Behmel A., Lorenzo M. J. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer. 1995 Mar;12(3):209–212. doi: 10.1002/gcc.2870120308. [DOI] [PubMed] [Google Scholar]
  9. Eng C., Ponder B. A. The role of gene mutations in the genesis of familial cancers. FASEB J. 1993 Jul;7(10):910–919. doi: 10.1096/fasebj.7.10.8102106. [DOI] [PubMed] [Google Scholar]
  10. Eng C., Smith D. P., Mulligan L. M., Healey C. S., Zvelebil M. J., Stonehouse T. J., Ponder M. A., Jackson C. E., Waterfield M. D., Ponder B. A. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 1995 Feb 2;10(3):509–513. [PubMed] [Google Scholar]
  11. Eng C., Smith D. P., Mulligan L. M., Nagai M. A., Healey C. S., Ponder M. A., Gardner E., Scheumann G. F., Jackson C. E., Tunnacliffe A. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994 Feb;3(2):237–241. doi: 10.1093/hmg/3.2.237. [DOI] [PubMed] [Google Scholar]
  12. Feinberg A. P. A developmental context for multiple genetic alterations in Wilms' tumor. J Cell Sci Suppl. 1994;18:7–12. doi: 10.1242/jcs.1994.supplement_18.2. [DOI] [PubMed] [Google Scholar]
  13. Foster K., Prowse A., van den Berg A., Fleming S., Hulsbeek M. M., Crossey P. A., Richards F. M., Cairns P., Affara N. A., Ferguson-Smith M. A. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet. 1994 Dec;3(12):2169–2173. doi: 10.1093/hmg/3.12.2169. [DOI] [PubMed] [Google Scholar]
  14. Gnarra J. R., Tory K., Weng Y., Schmidt L., Wei M. H., Li H., Latif F., Liu S., Chen F., Duh F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994 May;7(1):85–90. doi: 10.1038/ng0594-85. [DOI] [PubMed] [Google Scholar]
  15. Gutmann D. H., Geist R. T., Rose K., Wallin G., Moley J. F. Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1. Genes Chromosomes Cancer. 1995 Jun;13(2):104–109. doi: 10.1002/gcc.2870130206. [DOI] [PubMed] [Google Scholar]
  16. Hofstra R. M., Landsvater R. M., Ceccherini I., Stulp R. P., Stelwagen T., Luo Y., Pasini B., Höppener J. W., van Amstel H. K., Romeo G. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994 Jan 27;367(6461):375–376. doi: 10.1038/367375a0. [DOI] [PubMed] [Google Scholar]
  17. Komminoth P., Kunz E., Hiort O., Schröder S., Matias-Guiu X., Christiansen G., Roth J., Heitz P. U. Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing. Am J Pathol. 1994 Oct;145(4):922–929. [PMC free article] [PubMed] [Google Scholar]
  18. Lamiell J. M., Salazar F. G., Hsia Y. E. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989 Jan;68(1):1–29. doi: 10.1097/00005792-198901000-00001. [DOI] [PubMed] [Google Scholar]
  19. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317–1320. doi: 10.1126/science.8493574. [DOI] [PubMed] [Google Scholar]
  20. Lindor N. M., Honchel R., Khosla S., Thibodeau S. N. Mutations in the RET protooncogene in sporadic pheochromocytomas. J Clin Endocrinol Metab. 1995 Feb;80(2):627–629. doi: 10.1210/jcem.80.2.7852530. [DOI] [PubMed] [Google Scholar]
  21. Maher E. R., Yates J. R., Harries R., Benjamin C., Harris R., Moore A. T., Ferguson-Smith M. A. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990 Nov;77(283):1151–1163. doi: 10.1093/qjmed/77.2.1151. [DOI] [PubMed] [Google Scholar]
  22. Mathew C. G., Smith B. A., Thorpe K., Wong Z., Royle N. J., Jeffreys A. J., Ponder B. A. Deletion of genes on chromosome 1 in endocrine neoplasia. Nature. 1987 Aug 6;328(6130):524–526. doi: 10.1038/328524a0. [DOI] [PubMed] [Google Scholar]
  23. Mulligan L. M., Eng C., Attié T., Lyonnet S., Marsh D. J., Hyland V. J., Robinson B. G., Frilling A., Verellen-Dumoulin C., Safar A. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet. 1994 Dec;3(12):2163–2167. doi: 10.1093/hmg/3.12.2163. [DOI] [PubMed] [Google Scholar]
  24. Mulligan L. M., Eng C., Healey C. S., Clayton D., Kwok J. B., Gardner E., Ponder M. A., Frilling A., Jackson C. E., Lehnert H. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994 Jan;6(1):70–74. doi: 10.1038/ng0194-70. [DOI] [PubMed] [Google Scholar]
  25. Mulligan L. M., Gardner E., Smith B. A., Mathew C. G., Ponder B. A. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosomes Cancer. 1993 Mar;6(3):166–177. doi: 10.1002/gcc.2870060307. [DOI] [PubMed] [Google Scholar]
  26. Mulligan L. M., Kwok J. B., Healey C. S., Elsdon M. J., Eng C., Gardner E., Love D. R., Mole S. E., Moore J. K., Papi L. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993 Jun 3;363(6428):458–460. doi: 10.1038/363458a0. [DOI] [PubMed] [Google Scholar]
  27. Neumann H. P. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa. 1987;16(3):220–226. [PubMed] [Google Scholar]
  28. Neumann H. P., Berger D. P., Sigmund G., Blum U., Schmidt D., Parmer R. J., Volk B., Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1993 Nov 18;329(21):1531–1538. doi: 10.1056/NEJM199311183292103. [DOI] [PubMed] [Google Scholar]
  29. Riccardi V. M. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981 Dec 31;305(27):1617–1627. doi: 10.1056/NEJM198112313052704. [DOI] [PubMed] [Google Scholar]
  30. Schimke R. N. Multiple endocrine neoplasia: how many syndromes? Am J Med Genet. 1990 Nov;37(3):375–383. doi: 10.1002/ajmg.1320370317. [DOI] [PubMed] [Google Scholar]
  31. Vasen H. F., Nieuwenhuijzen Kruseman A. C., Berkel H., Beukers E. K., Delprat C. C., Van Doorn R. G., Geerdink R. A., Haak H. R., Hackeng W. H., Koppeschaar H. P. Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration. A study of 15 kindreds in The Netherlands. Am J Med. 1987 Nov;83(5):847–852. doi: 10.1016/0002-9343(87)90641-3. [DOI] [PubMed] [Google Scholar]
  32. Whaley J. M., Naglich J., Gelbert L., Hsia Y. E., Lamiell J. M., Green J. S., Collins D., Neumann H. P., Laidlaw J., Li F. P. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet. 1994 Dec;55(6):1092–1102. [PMC free article] [PubMed] [Google Scholar]
  33. Zedenius J., Wallin G., Hamberger B., Nordenskjöld M., Weber G., Larsson C. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet. 1994 Aug;3(8):1259–1262. doi: 10.1093/hmg/3.8.1259. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES